<html>
<head>
<meta charset="UTF-8"/>
<meta name="tikaGenerated" content="true"/>
<meta name="date" content="2017-05-09T06:30:31Z"/>
<meta name="creator" content="Rebecca Smith"/>
<meta name="xmp:CreatorTool" content="Adobe Acrobat Pro 11.0.6"/>
<meta name="meta:author" content="Rebecca Smith"/>
<meta name="meta:creation-date" content="2017-05-09T06:30:31Z"/>
<meta name="created" content="Tue May 09 16:00:31 ACST 2017"/>
<meta name="dc:creator" content="Rebecca Smith"/>
<meta name="xmpTPg:NPages" content="4"/>
<meta name="Creation-Date" content="2017-05-09T06:30:31Z"/>
<meta name="dcterms:created" content="2017-05-09T06:30:31Z"/>
<meta name="Last-Modified" content="2017-05-09T06:30:31Z"/>
<meta name="dcterms:modified" content="2017-05-09T06:30:31Z"/>
<meta name="Last-Save-Date" content="2017-05-09T06:30:31Z"/>
<meta name="meta:save-date" content="2017-05-09T06:30:31Z"/>
<meta name="Author" content="Rebecca Smith"/>
<meta name="producer" content="Adobe Acrobat Pro 11.0.6"/>
<meta name="modified" content="2017-05-09T06:30:31Z"/>
<meta name="Content-Type" content="application/pdf"/>
</head>
<body>
<pre>
 
Version control and change history 
 
Version Date from Date to Amendment 
1.0 November 2012 April 2017 Original version 
2.0 28 April 2017 Current Complete review 
    
    

  Department for Health and Ageing, Government of South Australia. All rights reserved. 

 

Clinical Guideline 
Cefotaxime 
 
 
Policy developed by: SA Maternal &amp; Neonatal Clinical Community of Practice       
Approved by 
Safety &amp; Quality Strategic Governance Committee on:  27 April 2017 
Next review due:         30 April 2020 
 
 
 

  
 
 

Summary The purpose of this Cefotaxime  Neonatal Medication Guideline is 
to guide nursing, medical and pharmacy staff in the dosing and 
administration of cefotaxime  
 
 

Keywords Cefotaxime, neonatal medication guideline, infection, sepsis, 
ceftriaxone, cephalosporin, clostridium difficile, c.diff, clinical 
guideline,  Cefotaxime  Neonatal Medication Guideline 
 

Policy history Is this a new policy?   N 
Does this policy amend or update an existing policy?  Y v1.0 
Does this policy replace an existing policy?  N 
If so, which policies?   
 

Applies to All Health Networks 
CALHN, SALHN, NALHN, CHSALHN, WCHN 
 

Staff impact All Clinical, Medical, Midwifery, Nursing,  Students, Allied Health, 
Emergency, Mental Health, Pathology, Pharmacy 
  

PDS reference CG018 
 

Neonatal Medication Guideline                                                             
 

 



South Australian Neonatal Medication Guidelines 

cefOTAXIME  
 1g  injection 

  Department of Health, Government of South Australia. All rights reserved 

 

ISBN number:  978-1-74243-387-5 
Endorsed by:                         South Australian Maternal, Neonatal &amp; Gynaecology Clinical Reference Group 
Last Revised: 27/04/2017 
Contact: South Australian Neonatal Medication Guidelines Workgroup at: 

 Health:NeoMed@sa.gov.au  Page 1 of 3 
 

Note 
 
This guideline provides advice of a general nature.  This statewide guideline has been prepared to promote and facilitate 
standardisation and consistency of practice, using a multidisciplinary approach.  The guideline is based on a review of 
published evidence and expert opinion.  

Information in this statewide guideline is current at the time of publication.  

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not 
sponsor, approve or endorse materials on such links. 

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and 
professionally assess the applicability of the relevant guideline to that clinical situation. 

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the 
patient s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline. 

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are 
responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful 
confidential discussion. This includes: 

  The use of interpreter services where necessary, 
  Advising consumers of their choice and ensuring informed consent is obtained, 
  Providing care within scope of practice, meeting all legislative requirements and maintaining standards of 

professional conduct, and  
  Documenting all care in accordance with mandatory and local requirements 
 
 

Dose and Indications 

1g = 1000mg  

Infection due to susceptible organisms 

Intravenous, Intramuscular 

50mg/kg/dose 

Corrected Age (weeks) 

[Gestational Age PLUS Postnatal Age] 

Postnatal age 

(days) 
Frequency (hours) 

&lt;30 
? 28 every 12 hours 

&gt; 28 every 8 hours 

30 to 36 
? 14 every 12 hours 

&gt; 14 every 8 hours 

37 to 44 
? 7 every 12 hours 

&gt; 7 every 8 hours 

 

Length of treatment should be guided by pathology and clinical picture; however in proven 

sepsis treatment should continue for a minimum of 7 days. 

 



South Australian Neonatal Medication Guidelines 

 cefOTAXIME  
 1g  injection 

 

ISBN number:  978-1-74243-387-5 
Endorsed by:                         South Australian Maternal, Neonatal &amp; Gynaecology Clinical Reference Group 
Last Revised: 27/04/2017 
Contact: South Australian Neonatal Medication Guidelines Workgroup at: 

 Health:NeoMed@sa.gov.au  Page 2 of 3 
 

Preparation and Administration 

Intravenous 

Vial Strength 

(mg) 

Volume of Water for Injection to 

add (mL) 

Final Concentration of cefOTAXIME 

(mg/mL) 

1000mg 9.6mL 100mg/mL 

Shake vigorously to dissolve 

 

Dose 25mg 50mg 75mg 100mg 125mg 150mg 

Volume 0.25mL 0.5mL 0.75mL 1mL 1.25mL 1.5mL 

Administer intravenously over at least 3 minutes  

 

Intramuscular 

Vial Strength 

(mg) 

Volume of Water for Injection to 

add (mL) 

Final Concentration of cefOTAXIME 

(mg/mL) 

1000mg 3.6mL 250mg/mL 

Shake vigorously to dissolve 

 

Dose 25mg 50mg 75mg 100mg 125mg 150mg 

Volume 0.1mL 0.2mL 0.3mL 0.4mL 0.5mL 0.6mL 

Administer as an IM injection 

Compatible Fluids 

Glucose 5%, glucose 10%, sodium chloride 0.9%, Hartmann s 

Adverse Effects 

Common 

Diarrhoea, vomiting, pain and inflammation at injection site, rash, Clostridium difficile-

associated disease, superinfection  

Infrequent 

Neurotoxicity (seizures, encephalopathy) particularly with high doses and/or renal impairment, 

blood dyscrasias, (neutropenia related to dose and treatment duration, thrombocytopenia) 

Anaphylactic shock is not commonly seen in neonates 





South Australian Neonatal Medication Guidelines 

 cefOTAXIME  
 1g  injection 

 

ISBN number:  978-1-74243-387-5 
Endorsed by:                         South Australian Maternal, Neonatal &amp; Gynaecology Clinical Reference Group 
Last Revised: 27/04/2017 
Contact: South Australian Neonatal Medication Guidelines Workgroup at: 

 Health:NeoMed@sa.gov.au  Page 3 of 3 
 

Version control and change history 

PDS reference: OCE use only 

 
Version Date from Date to Amendment 

1.0 November 2012 April 2017 Original version 

2.0 April 2017 Current Complete review 

    

    

 
 

Practice Points 

? The use of third generation cephalosporins should be limited to the management of proven 

or highly likely Gram-negative septicaemia and meningitis to minimise the emergence of 

resistant strains  

? CefOTAXIME is used instead of cefTRIAXONE for gram-negative septicaemia in neonates 

because cefTRIAXONE can displace bilirubin, thus precipitating kernicterus. 

? Protect from light during storage. 

 


	Cefotaxime_Neo_Cover_v2
	Clinical Guideline
	Cefotaxime
	Policy developed by: SA Maternal &amp; Neonatal Clinical Community of Practice
	Approved by
	Safety &amp; Quality Strategic Governance Committee on:  27 April 2017
	Next review due:         30 April 2020

	Cefotaxime_Neo_v2

</pre>
</body>
</html>